Mahmoud Gaballa, MD

Peer-Reviewed Articles

1. Fortuna, GG, Peres, LC, Nazarenko, E, de Menezes Silva Corraes, A, Hovanky, V, Shune, L, McGuirk, J, De Avilla, G, Khouri, J, Dima, D, Gaballa, MM, Dhakal, B, Forsberg, P, Godara, A, Afrough, A, Anderson, L, Herr, M, Davis, JA, Mann, H, Purvey, S, Clark, WB, Htut, M, Beitinjaneh, AM, Pereira, D, Kocoglu, MH, Ferreri, C, Atrash, S, Voorhees, PM, Rossi, A, Shambavi, R, Hashmi, H, Patel, K, Sidana, S, Lin, Y, Hansen, DK, Sborov, D. Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia. Blood Advances 9(23):6009-6018, 2025. e-Pub 2025. PMID: 40875887.
2. Pasvolsky, O, Dima, D, Feng, L, Dong, W, Richards, TA, Davis, JA, Afrough, A, Vazquez-Martinez, M, Sannareddy, A, Goel, U, Banerjee, R, Khouri, J, Cervoni, F, Gaballa, MM, Lieberman-Cribbin, A, Rana, MS, Julian, K, Ferreri, C, Shune, L, DeJarnette, S, Bhurtel, E, Susanibar-Adaniya, SP, Portuguese, AJ, Hosoya, H, Mikkilineni, L, Kaur, G, Rossi, A, Herr, M, Schrum, D, Lin, C, Raza, S, Lin, Y, Midha, S, Omar, N, Atarsh, S, McGuirk, J, Sborov, D, Voorhees, PM, Anwer, F, Alsina, M, Freeman, C, Garfall, A, Razzo, B, Sidana, S, Cowan, AJ, Anderson, L, Hansen, DK, Richard, S, Patel, K, Lee, HC, Grajales-Cruz, A. Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40346049.
3. Sweiss, K, Wagner, C, Anto, E, Greene, T, Sun, R, Gonzalez, R, Castaneda Puglianini, OA, Freeman, C, Ionescu, F, Patel, K, Ferreri, C, Gaballa, MM, Shune, L, McGuirk, J, Sidana, S, Hovanky, V, Khouri, J, Raza, S, Anwer, F, Dima, D, Hashmi, H, Davis, JA, Afrough, A, Kaur, G, Anderson, L, Forsberg, P, Herr, M, Hansen, DK, Hakan Kocoglu, M, Sborov, D. Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma. Transplantation and Cellular Therapy 31(12):989-999, 2025. e-Pub 2025. PMID: 40972962.
4. Dima, D, Vazquez-Martinez, M, Davis, JA, Goel, U, Afrough, A, Sannareddy, A, Pasvolsky, O, Razzo, B, Banerjee, R, Khouri, J, Grajales-Cruz, A, Lieberman-Cribbin, A, Rana, MS, Julian, K, DeJarnette, S, Portuguese, AJ, Gaballa, MM, De Avila, G, Susaniba Adaniya, S, Raza, S, Herr, M, Ouchveridze, E, Richards, TA, Hosoya, H, Mikkilineni, L, Kaur, G, Castaneda Puglianini, OA, Rossi, A, Lin, Y, Atrash, S, Sborov, D, Shain, KH, Voorhees, PM, Richard, S, Garfall, A, Hansen, DK, Sidana, S, Patel, K, Cowan, AJ, Anderson, L, Lee, HC, Anwer, F, Ferreri, C, Shune, L. Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40562770.
5. Dhakal, B, Akhtar, O, Fandrei, D, Jensen, A, Banerjee, R, Pan, D, Richard, S, Friend, R, Rees, MJ, Costello, P, Vazquez-Martinez, M, Pasvolsky, O, Wagner, C, Davis, JA, Castaneda Puglianini, OA, Reshef, R, Afrough, A, Dima, D, Bhutani, M, Nadeem, O, Parrondo, RD, Freeman, C, Mikkilineni, L, Raza, S, Anderson, L, Kapoor, P, Hosoya, H, Chhabra, S, Grajales-Cruz, A, Gaballa, MM, Midha, S, Alsina, M, Sborov, D, Patel, K, Lin, Y, Ferreri, C, Gagelmann, N, Kumar, A, Hansen, DK, Cowan, AJ, Costa, LM, Merz, M, Sidana, S. Sequential targeting in multiple myeloma. Blood 146(17):2063-2072, 2025. e-Pub 2025. PMID: 40749169.
6. Dima, D, Afrough, A, Goel, U, Grajales-Cruz, A, Khouri, J, Julian, K, Pasvolsky, O, Banerjee, R, Razzo, B, Ferreri, C, Vazquez-Martinez, M, Davis, JA, Sannareddy, A, Castaneda, O, Raza, S, Portuguese, AJ, Gaballa, MM, Rana, MS, Lieberman-Cribbin, A, DeJarnette, S, Gonzalez, R, Chen, A, Herr, M, Mikkilineni, L, Hosoya, H, Ouchveridze, E, Kaur, G, Rossi, A, Shune, L, Anwer, F, Lin, Y, Richard, S, Sborov, D, Baz, R, Garfall, A, Lee, HC, Anderson, L, Cowan, AJ, Patel, K, Voorhees, PM, Sidana, S, Hansen, DK, Atrash, S, Susanibar-Adaniya, SP. Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment. Blood Advances 9(14):3408-3417, 2025. e-Pub 2025. PMID: 40198766.
7. Saha, S, Rehman, L, Rehman, A, Darbaniyan, F, Weber, DM, Becnel, M, Gaballa, MM, Thomas, SK, Lee, HC, Chang, C, Arora, R, Menges, M, Corallo, SA, Davila, ML, Locke, FL, Tanner, MR, Neelapu, SS, Shpall, E, Flowers, CR, Orlowski, R, Jenq, RR, Jain, MD, Peterson, CB, Hansen, DK, Saini, N, Patel, K. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Advances 9(14):3429-3440, 2025. e-Pub 2025. PMID: 40198765.
8. Pasvolsky, O, Abid, MB, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Jatoi, A, Khan, HN, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Siddiqui, U, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Gaballa, MM, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. British Journal of Haematology 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
9. Hansen, DK, Peres, LC, Dima, D, Richards, A, Shune, L, Afrough, A, Midha, S, Dhakal, B, Kocoglu, MH, Atrash, S, Ferreri, C, Castaneda, O, Davis, JA, Bhurtel, E, McGuirk, J, Wagner, C, Bansal, R, Costello, P, Smith, K, Lieberman-Cribbin, A, De Avila, G, Purvey, S, Hosoya, H, Mikkilineni, L, Oswald, LB, Kaur, G, Pasvolsky, O, Gaballa, MM, Herr, M, Forsberg, P, Janakiram, M, Htut, M, Asoori Maringanti, S, Kalariya, N, Hashmi, H, Reshef, R, Sborov, D, Nadeem, O, Anwer, F, Khouri, J, Raza, S, Atanackovic, D, Alsina, M, Freeman, C, Locke, FL, Voorhees, PM, Anderson, L, Richard, S, Martin, T, Lin, Y, Patel, K, Sidana, S. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology 43(13):1597-1609, 2025. e-Pub 2025. PMID: 39965175.
10. Gaballa, MM, Castaneda Puglianini, OA, Cohen, AD, Vogl, DT, Chung, A, Ferreri, C, Voorhees, PM, Hansen, DK, Patel, K. BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Advances 9(5):1171-1180, 2025. e-Pub 2025. PMID: 39729503.
11. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
12. Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14); The MD Anderson Cancer Center Experience. Transplant Cell Ther 29(4):S2666-6367, 2023. e-Pub 2023. PMID: 36646323.
13. Dhawale TM, Johnson PC, Gaballa MR, Nelson AM, Lavoie MW, Boateng KY, Greydanus C, Frigault MJ, El-Jawahri A. Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy. Cancer 129(3):441-449, 2023. e-Pub 2023. PMID: 36457279.
14. Singh, H, Srour, S, Milton, D, McCarty, J, Dai, C, Gaballa, MM, Ammari, M, Olivares, S, Huls, H, de Groot, E, Marin, D, Petropoulos, D, Olson, AL, Anderlini, P, Im, JS, Khouri, IF, Hosing, C, Rezvani, K, Champlin, RE, Shpall, E, Cooper, L, Kebriaei, P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Frontiers in immunology 13, 2022. e-Pub 2022. PMID: 36439104.
15. Johnson, PC, Jacobson, C, Yi, A, Gaballa, MM, Horick, NK, Rabideau, DJ, Lindell, K, Depinho, GD, El-Jawahri, A, Frigault, M. Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy. Journal for immunotherapy of cancer 10(9), 2022. e-Pub 2022.
16. Gaballa, MM, Ma, J, Rauf, M, Bassett Jr, R, Pasvolsky, O, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Murphy, R, Rezvani, K, Tang, G, Lin, P, Lee, HC, Patel, K, Ullah, MR, Kaufman, GP, Manasanch, EE, Kebriaei, P, Thomas, SK, Weber, DM, Shpall, E, Champlin, RE, Orlowski, R, Qazilbash, MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone marrow transplantation 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
17. Gaballa, MM, Banerjee, PP, Milton, D, Jiang, XL, Ganesh, C, Khazal, SJ, Nandivada, V, Islam, S, Kaplan, M, Daher, M, Basar, R, Alousi, AM, Mehta, RS, Al-Atrash, G, Khouri, IF, Oran, B, Marin, D, Popat, UR, Olson, AL, Tewari, P, Jain, N, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Chen, K, Champlin, RE, Shpall, E, Rezvani, K, Kebriaei, P. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood 139(12):1908-1919, 2022. e-Pub 2022. PMID: 34914826.
18. Gaballa, MM, Ma, J, Tanner, MR, Al-Juhaishi, T, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Murphy, R, Rezvani, K, Tang, G, Lee, HC, Patel, K, Kaufman, GP, Manasanch, EE, Ullah, MR, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leukemia and Lymphoma 63(3):710-721, 2022. e-Pub 2022. PMID: 34686083.
19. Gaballa MR, Ma J, Rauf M, Tanner M, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee H, Patel K, Kaufmann G, Manasanch EE, Ullah MR, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. KRD vs.VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Multiple Myeloma. Bone Marrow Transplant, 2022. e-Pub 2022.
20. Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies, 2022. e-Pub 2022.
21. Gaballa MR, Maus MV. High antigen density of BCMA: Friend or Foe to CAR T cells?, 2022. e-Pub 2022.
22. Johnson PC, Jacobson C, Yi A, Gaballa MR, Horick N, Rabideau D, Lindell K, Depinho G, El-Jawahri A, Frigault MJ. Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. Journal for ImmunoTherapy of Cancer, 2022. e-Pub 2022.
23. Gaballa MR, Banerjee PP, Milton DR, Jiang X, Ganesh C, Khazal SJ, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta RS, Alatrash G, Khouri IF, Oran B, Marin D, Popat UR, Olson AL, Tewari P, Jain N, Jabbour EJ, Ravandi F, Kantarjian HM, Chen K, Champlin RE, Shpall EJ, Rezvani K, Kebriaei P. Blinatumomab maintenance after allogenic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood:1908-19, 2022. e-Pub 2022.
24. Gaballa MR, Ma J, Tanner M, Al-Juhaishi T, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvania K, Tang G, Lee H, Patel K, Kaufmann G, Manasanch EE, Ullah MR, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma:710-721, 2022. e-Pub 2022.
25. Gaballa MR, Kebriaei P. Advances in Cellular Immunotherapy in Hematologic Malignancies. Advances in Oncology:223-236, 2021. e-Pub 2021.
26. Jang A, Kram KN, Berger SN, Gaballa MR, Lu LB, Dunaway DR, Miller-Chism CN. Acute Lymphoblastic Leukemia Presenting Initially as Spinal Cord Compession: When Chemotherapy Alone is Enough. Case Rep Med, 2020. e-Pub 2020. PMID: 32273896.
27. Gaballa MR, Ramos CA. Cellular Immunotherapy in Lymphoma: Beyond CART Cells. Current treatment options in oncology, 2020. e-Pub 2020.
28. Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa MR. Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. Oncotarget:72395-72414, 2016. e-Pub 2016.
29. Alattar ML, Ciccone M, Gaballa MR, Vitale C, Badoux XC, Manoukian G, Keating MJ, Kroll MH, Ferrajoli A. Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. Leukemia Lymphoma:3452-3454, 2015. e-Pub 2015.
30. Gaballa MR, Besa EC. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Ann Hematol:723–733, 2014. e-Pub 2014.
31. Gaballa M, Farag Y. Predictors of diabetic nephropathy. Open Medicine:287-296, 2013. e-Pub 2013.
32. Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol:51-66, 2012. e-Pub 2012.
33. Farag YM, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant:28-35, 2011. e-Pub 2011.

Editorials

1. Gaballa, MM, Maus, MV. High antigen density of BCMA. Journal for immunotherapy of cancer 10(9), 2022. PMID: 36137650.

Abstracts

1. Rees M, Cassano RC, Tan M, Zolotov E, Sidana S, Dima D, Kort J, Afrough A, Gaballa M, Pasvolsky O, Mikkilineni L, Khouri J, Raza S, Zanwar S, Ferreri C, Khan A, Atrash S, Portuguese A, Hovanky V, Banerjee R, Freeman CL, Patel K, Anderson L, Castaneda Puglianini OA, Shune L, Biran N, Hansen D, Lin Y. The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis. ASH 2025. e-Pub 2025.
2. Zolotov E, Biran N, Roney P, Ahn J, Rees M, Banerjee R, Tan M, Sidana S, Dima D, DeJarnette S, Afrough A, Gaballa M, Pasvolsky O, Khouri J, Raza S, Goel U, Anwer F, Zanwar S, Lin Y, Atrash S, Reshef R, Gordillo C, Portuguese A, Cassano RC, Bhurtel E, Kort J, Shune L, Geer M, Xie Z, Castaneda Puglianini OA, Hansen D, Freeman CL, Locke F, Nishihori T, Grajales-Cruz A, Davis J, Green K, Herr M, Hassan H, Mikkilineni L, Hosoya H, Sannareddy A, Patel K, Anderson L, Khan A, Sborov D, Wagner C, Cahoon C, Fortuna GG, Purvey S, Ferreri C. Subsequent primary malignancies after CAR-T therapy: A study from the US Multiple Myeloma Immunotherapy Consortium, 2025. e-Pub 2025.
3. Joiner L, Pasvolsky O, Afrough A, Zanwar S, Banerjee R, Cassano RC, Gaballa M, Julian K, Grajales-Cruz A, Alsina M, Goel U, Corraes A, Dima D, Rana M, Hosoya H, Mikkilineni L, Fogel L, Raza S, Ali HM, Sannareddy A, Sborov D, Borogovac A, Janakiram M, Davis J, Green K, Biran N, Hassan H, Herr M, Shune L, Bhurtel E, Atrash S, Ferreri C, Midha S, Nadeem O, Castaneda Puglianini OA, Shain K, Abid MB, Voorhees P, Khouri J, Portuguese A, Lin Y, Sidana S, Hansen D, Patel K, Costa L, Bal S, Anderson L. Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI). e-Pub 2025.
4. Gaballa M, Julian K, Afrough A, Hansen D, Goel U, Silva Corraes ADM, Dima D, Rana M, Hosoya H, Mikkilineni L, Fogel L, Raza S, Banerjee R, Zanwar S, Pasvolsky O, Sannareddy A, Borogovac A, Davis J, Green K, Biran N, Herr M, Shune L, Bhurtel E, Atrash S, Ferreri C, Richards T, Abid MB, Bal S, Ali HM, Ye J, Richard S, Kaur G, Shain K, Castaneda Puglianini OA, Rossi A, Anderson L, Voorhees P, Khouri J, Sidana S, Portuguese A, Janakiram M, Lee H, Lin Y, Grajales-Cruz A, Patel K, Sborov D. Real world outcomes of bispecific T-cell engagers in plasma cell leukemia. ASH 2025. e-Pub 2025.
5. Lee J, Jensen A, Hosoya H, Zanwar S, Pasvolsky O, Gaballa M, Dillard C, Khouri J, Raza S, Goel U, Anwer F, Hovanky V, Rana M, Davis J, Green K, Afrough A, Anderson L, Biran N, Zolotov E, Herr M, Hassan H, Shune L, Kort J, Ferreri C, Atrash S, Varga C, Voorhees P, Sborov D, Fortuna G, Julian K, Dima D, Banerjee R, Freeman CL, Portuguese A, Cassano RC, Locke F, Salva KJ, Peres L, Reid B, Castaneda Puglianini OA, Grajales-Cruz A, Jain M, Patel K, Frank M, Lin Y, Hansen D, Sidana S, Shah N, Mikkilineni L. Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM). ASH 2025, 2025. e-Pub 2025.
6. dos Santos DMC, Rejeski K, Geyer SM, Dooley KE, Tix T, Bassermann F, Puglianini OC, Chhabra S, Costello P, Freeman CL, Frenking J, Gaballa M, Li Y, Nadeem O, Parrondo R, Pasvolsky O, Patel KK, Rajeeve S, Rana MS, Sidana S, Theurich S, Usmani SZ, Weisel K, Hansen DK, Lin Y. Development and Validation of the SCOPE‑MM Score Predicting Response and Toxicity to BCMA CAR‑T Therapy. International Myeloma Society Annual Meeting 2025. e-Pub 2025.
7. Afrough A, Pasvolsky O, Zanwar S, Gaballa M, Sannareddy A, Dima D, Goel U, Ali HM, Julian K, Corraes A, Cassano R, Janakiram M, Goldsmith S, Davis J, Green K, Biran N, Fogel L, Zolotov E, Herr M, Hassan H, Shune L, Kort J, Bal S, Costa L, Ye J, Joiner L, Raza S, Anwer F, Khouri J, Banerjee R, Portuguese A, Sidana S, Rana M, Mikkilineni L, Hosoya H, Atrash S, Ferreri C, Varga C, Sborov D, Midha S, Nadeem O, Grajales-Cruz A, Baz R, Blue B, Freeman CL, Locke F, Patel K, Lin Y, Kumar S, Hansen D, Anderson L, Voorhees P, Castaneda Puglianini OA. Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas. ASH 2025. e-Pub 2025.
8. Belwadi M, Hamilton M, Wang Y, Ahmed S, Richards D, Banerjee R, Kalariya N, Pabla B, Saini N, Pasvolsky O, Ye J, Gaballa M, Wang S, Medeiros L, Vega F, Patel K, Iyer S. Immune effector cell-associated enterocolitis (IEC-EC) across CAR-T products in myeloma and lymphoma: A real world pharmacovigilance analysis. ASH 2025. e-Pub 2025.
9. Velayati A, Jensen A, Dima D, Rana M, Peres L, Shune L, Reid B, Pasvolsky O, Portuguese A, Abdallah N, Hosoya H, Mikkilineni L, Banerjee R, Cassano RC, Khouri J, Ferreri C, Afrough A, Biran N, Purvey S, Fortuna G, Hovanky V, Sborov D, Julian K, Green K, Freeman CL, McGuirk J, Zolotov E, Varga C, Geer M, Puglianini O, Goel U, Gaballa M, Anwer F, Raza S, Dillard C, Zanwar S, Dahiya S, Miklos D, Davis J, Herr M, Alsina M, Lin Y, Voorhees P, Reshef R, Anderson L, Patel K, Hansen D, Sidana S. Safety and efficacy of BCMA directed CAR-T therapy in older patients (aged ≥75) with relapsed or refractory multiple myeloma (RRMM). ASH 2025, 2025. e-Pub 2025.
10. Lee J, Jensen A, Hosoya H, Afrough A, Zanwar S, Pasvolsky O, Gaballa M, Dillard C, Khouri J, Raza S, Goel U, Anwer F, Hovanky V, Rana M, Davis J, Green K, Anderson L, Biran N, Zolotov E, Herr M, Hassan H, Shune L, Kort J, Ferreri C, Atrash S, Varga C, Voorhees P, Sborov D, Fortuna G, Julian K, Dima D, Portuguese A, Banerjee R, Freeman CL, Salva KF, Cassano RC, Peres L, Reid B, Castaneda Puglianini OA, Grajales-Cruz A, Jain M, Patel K, Locke F, Frank M, Lin Y, Hansen D, Sidana S, Shah N, Mikkilineni L. Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma. ASH 2025, 2025. e-Pub 2025.
11. Gaballa M, Feng L, Afrough A, Banerjee R, Davis J, Borogovac A, Zanwar S, Julian K, Biran N, Castaneda Puglianini OA, Mikkilineni L, Ferreri C, Herr M, Shune L, Bhurtel E, Dima D, Pasvolsky O, Green K, Janakiram M, Hassan H, Kalariya N, Corraes A, Fogel L, Singhal R, Grajales-Cruz A, Blue B, Haider A, Sannareddy A, Seif S, Thomas S, Rana M, Ye J, Richards T, Hosoya H, Atrash S, Anderson L, Goldsmith S, Sidana S, Voorhees P, Sborov D, Lin Y, Portuguese A, Hansen D, Patel K. Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement. ASH 2025, 2025. e-Pub 2025.
12. Afrough A, Anderson L, Anwer F, Atrash S, Banerjee R, Castaneda O, Cowan A, Davis J, Avila GD, DeJarnette S, Dima D, Eberwein E, Ferreri C, Gaballa M, Garfall A, Goel U, Grajales-Cruz A, Hansen D, Herr M, Hosoya H, Julian K, Kaur G, Khouri J, Lee H, Lieberman-Cribbin A, Lin Y, Locke F, McGuirk J, Mikkilineni L, Ouchveridze E, Pasvolsky O, Patel K, Portuguese A, Rana M, Raza S, Razzo B, Richard S, Rossi A, Sannareddy A, Sborov D, Schrum D, Shune L, Sidana S, Susanibar-Adaniya S, Vasquez-Martinez M, Voorhees P. The Impact of Extramedullary Multiple Myeloma on Treatment Outcomes with Teclistamab: U.S. Myeloma Immunotherapy Consortium Real World Experience. ASH 2025, 2025. e-Pub 2025.
13. Zanwar S, Pasvolsky O, Hansen D, Goel U, Afrough A, Rana M, Portuguese A, Davis J, Sborov D, Bal S, Janakiram M, Shune L, Ferreri C, Biran N, Herr M, Hassan H, Grajales-Cruz A, Khouri J, Silva Corraes ADM, Kort J, Atrash S, Puglianini O, Baz R, Cassano RC, Liang E, Zolotov E, Ali HM, Varga C, Richards T, Hosoya H, Gaballa M, Dillard C, Fortuna GG, Lee L, Julian K, Green K, Sannareddy A, Anderson L, Alsina M, Raza S, Dima D, Mikkilineni L, Anwer F, Banerjee R, Krishnan A, Locke F, Voorhees P, Kumar S, Sidana S, Patel K, Dhakal B, Lin Y, Costa L. Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations. ASH 2025, 2025. e-Pub 2025.
14. Dillard C, Singhal R, Pasvolsky O, Nze C, Feng L, Hunzeker Z, Ye J, Thomas S, Becnel M, Gaballa M, Weber D, Richards T, Diaz F, Ahmed S, Hawkins M, Johnson N, Ow K, Adkins S, Lewis J, Kroll M, Orlowski R, Hildebrandt M, Patel K. Treatment history, not race or Duffy-null status, predicts outcomes with teclistamab in relapsed/refractory multiple myeloma. ASH 2025, 2025. e-Pub 2025.
15. Pleitez HG, Pasvolsky O, Feng L, Gaballa M, Hunzeker Z, Thomas S, Weber D, Kalariya N, Chen J, Abreu M, Varghese J, Hawkins M, Dillard C, Becnel M, Saini N, Qazilbash M, Bashir Q, Thakral B, Ye J, Kaufman G, Orlowski R, Wang S, Patel K. BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma. ASH 2025, 2025. e-Pub 2025.
16. Portuguese A, Davis J, Raza S, Castaneda Puglianini OA, Freeman CL, Alsina M, Wright C, Goel U, Khouri J, Anwer F, Ali HM, Pasvolsky O, Gaballa M, Patel K, Pleitez HG, Mikulski D, Fogel L, Zolotov E, Sannareddy A, Afrough A, Anderson L, Julian K, Dima D, Banerjee R, Liang E, Cassano RC, Herr M, Hassan H, Shune L, Kort J, Midha S, Nadeem O, Sidana S, Lin Y, Locke F, Hansen D, Sborov D, Biran N, Grajales-Cruz A. Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium. ASH 2025, 2025. e-Pub 2025.
17. Dang M, Seif S, Acevedo-Calado M, Wang L, Sanchez J, Gensini L, Bansal H, Becnel M, Gaballa M, Lee H, Pasvolsky O, Patel K, Weber D, Ye JC, Orlowski R, Thomas S. Single-cell transcriptomic and clonotypic characterization of Waldenstrom macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states. ASH 2025, 2025. e-Pub 2025.
18. Lionel AC, Seif S, Sun X, Feng L, Gensini L, Sanchez J, Becnel M, Gaballa M, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK. Impact of TP53 Mutation Status on Survival After First-Line Treatment in Lymphoplasmacytic Lymphoma. ASCO 2025, 2025. e-Pub 2025.
19. Dhakal B, Slade M, Mohamed M, Schroeder M, Narra RK, Akhtar O, Bansal H, Acevedo-Calado M, Pasvolsky O, Gaballa M, Becnel M, Weber D, Patel K, Thomas S, Ye JC, Mohan M, Pasquini M, Sun F, Stockerl-Goldstein K, D'Souza A, Vij R, Albitar M, Orlowski R, Lee H. Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM). ASH 2025, 2025. e-Pub 2025.
20. Sidana S, Reid B, Dima D, Peres L, Gaballa M, Banerjee R, Pasvolsky O, Afrough A, Dillard C, Ferreri C, Atrash S, Varga C, Portuguese A, Rana M, Hosoya H, Mikkilineni L, Hovanky V, Zanwar S, Kalariya N, Mikulski D, Wagner C, Cahoon C, Castaneda Puglianini OA, Avila GD, Gordillo C, Zolotov E, Grajales-Cruz A, Goel U, Sannareddy A, Kort J, Cassano R, Midha S, Davis J, Gonzalez R, Herr M, Xie Z, Hassan H, Purvey S, Geer M, Green K, Perna F, Liu H, Nishihori T, Khouri J, Raza S, Anwer F, Bal S, Nadeem O, Freeman CL, Shune L, Reshef R, Shain K, Alsina M, Baz R, Sborov D, Dahiya S, Locke F, Miklos D, Voorhees P, Anderson L, Costa L, Biran N, Kumar S, Lin Y, Patel K, Hansen D. Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality. ASH 2025, 2025. e-Pub 2025.
21. Dima D, Peres L, Shune L, Leitzinger C, Reid B, Portuguese A, Cassano RC, Banerjee R, Kalariya N, Pasvolsky O, Gaballa M, Hunzeker Z, Dillard C, Hosoya H, Mikkilineni L, Gonzalez R, Grajales-Cruz A, Castaneda Puglianini OA, Nishihori T, Wagner C, Cahoon C, Sborov D, Bhurtel E, Kort J, Geer M, Purvey S, Ferreri C, Varga C, Atrash S, Voorhees P, Goel U, Khouri J, Raza S, Anwer F, Afrough A, Sannareddy A, Anderson L, Hassan H, Herr M, Reshef R, Gordillo C, Zolotov E, Biran N, Davis J, Green K, Zanwar S, Lin Y, Costa L, Bal S, Midha S, Nadeem O, Alsina M, Baz R, Shain K, Locke F, Kumar S, Patel K, Sidana S, Hansen D. Identifying candidates for outpatient administration of ciltacabtagene autoleucel (cilta-cel) in relapsed-refractory multiple myeloma (RRMM). ASH 2025, 2025. e-Pub 2025.
22. Ye JC, Feng L, Gensini L, Thomas S, Irimia R, Pasvolsky O, Gaballa M, Becnel M, Saini N, Weber D, Dai L, Lin P, Lee H, Patel K, Orlowski R, Zou Y, Tang G, Gocke C. Genomic Profiling of Multiple Myeloma via Optical Genome Mapping: An Exploratory Analysis of Response and Progression in Newly Diagnosed and Relapsed Disease. International Myeloma Society Annual Meeting 2025, 2025. e-Pub 2025.
23. Pasvolsky O, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Haider A, Lee H, Patel K, Gaballa M, Kebriaei P, Thomas S, Orlowski R, Champlin R, Shpall E, Qazilbash M. DKRD vs. DVRD Induction Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. International Myeloma Society Annual Meeting 2025, 2025. e-Pub 2025.
24. Pasvolsky O, Grajales-Cruz A, Hansen D, Feng L, Dima D, Afrough A, Shain K, Banerjee R, Zanwar S, Anwer F, Hosoya H, Davis J, Sannareddy A, Lee L, Ye JC, Castaneda Puglianini OA, Neupane K, Richards T, Krishnan A, Biran N, Herr M, Raza S, Shune L, Bal S, Fogel L, Rana M, Hassan H, Ali HM, Baz R, Joiner L, Ferreri C, Green K, Janakiram M, Varga C, Fortuna GG, Gaballa M, Julian K, Mikkilineni L, Bhurtel E, Atrash S, Zolotov E, Sborov D, Voorhees P, Goel U, Anderson L, Portuguese A, Lee H, Khouri J, Sidana S, Costa L, Patel K, Lin Y. Talquetamab for relapsed/refractory multiple myeloma: Real-world outcomes from the US Multiple Myeloma Immunotherapy Consortium. ASH 2025, 2025. e-Pub 2025.
25. Gaballa M. Daratumumab, bortezomib, lenalidomide and dexamethasone, upfront autologous transplant and lenalidomide maintenance for newly diagnosed multiple myeloma. ASH 2025, 2025. e-Pub 2025.
26. Patel KK, Manasanch EE, Lee HC, Ye J, Thomas SK, Weber DM, Becnel MR, Gaballa MR, Bansal H, Berkova Z, Neelapu SS, Haymaker CL, Dang M, Wang L, Lizee G, Orlowski RZ. Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM). ASH 2024. e-Pub 2024.
27. Cervoni Curet FN, Bassett RL, Pasvolsky O, Deen AF, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Fingrut WB, Smallbone P, Becnel MR, Gaballa MR, Thomas SK, Ye J, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma. ASH 2024, 2024. e-Pub 2024.
28. Hansen DK, Peres LC, Dima D, Richards A, Shune LO, Afrough A, Midha S, Dhakal B, Kocoglu Atrash S, Ferreri C, Castaneda O, Davis JA, Ouchveridze E, McGuirk JP, Wagner CB, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, Avila GD, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa MR, Herr MM, Forsberg PA, Janakiram M, Htut M, Asoori S, Kalariya N, Hashmi HS, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees PM, Anderson Jr LD, Richard S, Martin T, Lin Y, P Patel KK, Sidana S. Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma. ASH 2024, 2024.
29. Pasvolsky O, Dima D, Feng L, Dong W, Richards T, PDavis JA, Afrough A, Vazquez-Martinez MA, Sannareddy A, Goel U, Banerjee R, Khouri J, Curet C, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune LO, DeJarnette S, Ouchveridze E, Susanibar-Adaniya S, Portuguese AJ, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Atrash S, McGuirk JP, Sborov DW, Voorhees PM, Anwer F, Alsina M, Freeman CL, Garfall AL, Sidana S, Cowan AJ, Anderson Jr LD, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A. Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. ASH 2024, 2024.
30. Rejeski K, Hansen DK, Dos Santos DMC, Silva Corraes ADM, Castaneda O, Dillard CM, Alsdorf W, Frenking JH, Purcarea A, Chhabra S, Freeman CL, Friedrich MJ, Gaballa MR, Gonzalez R, Bin Waqar SH, Hwa YL, Jain MD, Parrondo RD, Pasvolsky O, Shahbaz W, Shouval R, Spiess G, Stephens H, Theurich S, Bassermann F, Hecker JS, Raab MS, Weisel KC, Locke FL, Subklewe M, Patel KK, Lin Y. Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma. ASH 2024, 2024.
31. Frigault M, Rosenblatt J, Dhakal B, Raje N, Cook D, Gaballa MR, Emmanuel-Alejandro E, Nissen D, Cornwell C, Banerjee K, Rotte A, Heery C, Avigan D, Jakubowiak A, Bishop M. Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma, 2022. e-Pub 2022.
32. Gaballa MR, Ma J, Rauf M, Tanner M, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvania K, Tang G, Lin P, Lee H, Patel K, Kaufmann G, Manasanch EE, Ullah MR, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. KRD vs.VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Multiple Myeloma. Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2022. e-Pub 2022.
33. Frigault M, Rosenblatt J, Raje N, Cook D, Gaballa M, Emmanuel-Alejandro E, Cornwell C, Banerjee K, Rotte A, Heery C, Avigan D, Jakubowiak A, Bishop M. OAB-003: Phase 1 study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory multiple myeloma, 2022. e-Pub 2022.
34. Frigault M, Rosenblatt J, Raje N, Cook D, Gaballa M, Emmanuel-Alejandro E, Cornwell C, Banerjee K, Rotte A, Heery C, Avigan D, Jakubowiak A, Bishop M. OAB-003: Phase 1 study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory multiple myeloma, 2022. e-Pub 2022.
35. Gaballa MR, Ma J, Rauf M, Tanner M, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvania K, Tang G, Lin P, Lee H, Patel K, Kaufmann G, Manasanch EE, Ullah MR, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. KRD vs.VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Multiple Myeloma. Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2022. e-Pub 2022.
36. Frigault M, Rosenblatt J, Dhakal B, Raje N, Cook D, Gaballa MR, Emmanuel-Alejandro E, Nissen D, Cornwell C, Banerjee K, Rotte A, Heery C, Avigan D, Jakubowiak A, Bishop M. Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma, 2022. e-Pub 2022.
37. Hester RH, Rivera ZR, Whited LK, Ramdial JL, Aiss MA, Richardson IE, McCray LR, Mbadugha AG, Afrough A, Alsfeld LC, Gaballa MR, Belling M, Franco-Vega M, Vadhan- Raj S, Popat UR. Improving overnight handoffs on the stem cell transplant service through use of an electronic handoff, 2021. e-Pub 2021.
38. Gaballa MR, Ma J, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Lee H, Patel K, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Long-Term Outcomes of Multiple Myeloma Patients Treated with VRD Induction, Autologous Hematopoietic Cell Transplantation with Melphalan 200 Mg/m2 Conditioning, and Lenalidomide Maintenance, 2021. e-Pub 2021.
39. Gaballa MR, Ma J, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Lee H, Patel K, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Long-Term Outcomes of Multiple Myeloma Patients Treated with VRD Induction, Autologous Hematopoietic Cell Transplantation with Melphalan 200 Mg/m2 Conditioning, and Lenalidomide Maintenance, 2021. e-Pub 2021.
40. Hester RH, Rivera ZR, Whited LK, Ramdial JL, Aiss MA, Richardson IE, McCray LR, Mbadugha AG, Afrough A, Alsfeld LC, Gaballa MR, Belling M, Franco-Vega M, Vadhan- Raj S, Popat UR. Improving overnight handoffs on the stem cell transplant service through use of an electronic handoff, 2021. e-Pub 2021.
41. Gaballa MR, Al-Juhaishi T, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Lee H, Patel K, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes of Patients with Multiple Myeloma who Received VRD Induction, Autologous Hematopoietic Cell Transplantation, and Lenalidomide Maintenance, 2020. e-Pub 2020.
42. Gaballa M, Jang A, Hamad H, Bulsara S, Wu M, Carrum G, Ramos CA, Kamble R, Hill L, Pingali SR, Vu N, Scholoff A, Obi G, Heslop HE, Lulla PD. Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center. J Clin Oncol, 2020. e-Pub 2020.
43. Ramdial JL, Gaballa MR, Al-Juhaishi T. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood:11-13, 2020. e-Pub 2020.
44. Gaballa MR, Al-Juhaishi T, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Lee H, Patel K, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes of Patients with Multiple Myeloma who Received VRD Induction, Autologous Hematopoietic Cell Transplantation, and Lenalidomide Maintenance, 2020. e-Pub 2020.
45. Gaballa M, Jang A, Hamad H, Bulsara S, Wu M, Carrum G, Ramos CA, Kamble R, Hill L, Pingali SR, Vu N, Scholoff A, Obi G, Heslop HE, Lulla PD. Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center. J Clin Oncol, 2020. e-Pub 2020.
46. Ramdial JL, Gaballa MR, Al-Juhaishi T. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood:11-13, 2020. e-Pub 2020.
47. Jang A, Huo L, Gaballa M, Hester R, Musunuru T, Chen N, Udden M, Mims M. Double trouble: simultaneous cutaneous lymphomas in an AIDS patient, 2019. e-Pub 2019.
48. Kram K, Jang A, Berger S, Gaballa M, Robinson M. Of all the causes of back pain: acute lymphoblastic leukemia presenting with spinal cord compression, 2019. e-Pub 2019.
49. Jang A, Gaballa MR, Hamad H, Bulsara S, Wu M, Kamble R, Ramos CA, Carrum G, Hill L, Vu N, Scholoff A, Obi G, Heslop H, Lulla P. Infection burden in T-cell depleted alternative-donor hematopoietic stem cell transplant recipients compared with recipients of matched related donor HSCT: a single-center experience, 2019. e-Pub 2019.
50. Jang A, Gaballa MR, Hamad H, Bulsara S, Wu M, Kamble R, Ramos CA, Carrum G, Hill L, Vu N, Scholoff A, Obi G, Heslop H, Lulla P. Infection burden in T-cell depleted alternative-donor hematopoietic stem cell transplant recipients compared with recipients of matched related donor HSCT: a single-center experience, 2019. e-Pub 2019.
51. Jang A, Huo L, Gaballa M, Hester R, Musunuru T, Chen N, Udden M, Mims M. Double trouble: simultaneous cutaneous lymphomas in an AIDS patient, 2019. e-Pub 2019.
52. Kram K, Jang A, Berger S, Gaballa M, Robinson M. Of all the causes of back pain: acute lymphoblastic leukemia presenting with spinal cord compression, 2019. e-Pub 2019.
53. Fillmore N, Yellapragada S, White PS, Ifeorah C, Gaballa MR, Rivero G, Pyarajan S, Do N, Brophy M, Munshi N. Lack of racial disparity in outcome of African American (A.A.) and Caucasian patients with symptomatic multiple myeloma (MM) at the Veterans Affairs (V.A.) hospitals. Journal of Clinical Oncology, 2018. e-Pub 2018.
54. Fillmore N, Yellapragada S, White PS, Ifeorah C, Gaballa MR, Rivero G, Pyarajan S, Do N, Brophy M, Munshi N. Lack of racial disparity in outcome of African American (A.A.) and Caucasian patients with symptomatic multiple myeloma (MM) at the Veterans Affairs (V.A.) hospitals. Journal of Clinical Oncology, 2018. e-Pub 2018.
55. Ahmed S, Marcoux C, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Deeba R, Tang G, Aljawai Y, Lee H, Patel K, Gaballa M, Kebriaei P, Thomas S, Orlowski R, Champlin R, Shpall E, Qazilbash M, Pasvolsky O. Outcomes of Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant Following VRD or KRD Induction Therapy. International Myeloma Society Annual Meeting 2025.
56. Midha S, Gurumurthi A, Costello P, Redd RA, Freeman CL, Castaneda O, Gonzalez R, Ionescu F, Gaballa M, Kalariya N, Khouri J, Dima D, Kocoglu MH, Sborov D, Wagner CB, Atrash S, Voorhees PM, Hashmi H, Davis JA, Forsberg PA, McGuirk JP, Shune L, Herr M, Reshef R, Lin Y, Htut M, Martin T, Sidana S, Hansen DK, Nadeem O, Patel KK. Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma. ASH 2023.
57. Kaur G, De Avila G, Gaballa M, Midha S, Davis J, Wagner C, McGuirk JP, Forsberg P, Reshef R, Lin Y, Afrough A, Anderson Jr LD, Davila ML, Kocoglu MH, Sborov D, Htut M, Hashmi H, Sidana S, Chowdhury A, Patel KK, Hansen DK, Atrash S. Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database. American Society for Transplantation and Cellular Therapy Annual Meeting 2024.
58. Dang M, Seif S, Acevedo-Calado MJ, Wang L, Gabriel B, Lewis LS, Gensini L, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Weber DM, Ye J, Orlowski RZ, Sheeba K. Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis. ASH 2024.
59. Ye J, Tang G, Pasvolsky O, Becnel MR, Gaballa MR, Patel KK, Lee HC, Thomas SK, Weber DM, Lin P, Orlowski RZ. Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma. ASH 2024.
60. Pasvolsky O, Afrough A, Feng L, Dong W, Richards T, Davis JA, Dima D, Grajales-Cruz A, Vazquez-Martinez MA, Sannareddy A, Goel U, Banerjee R, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, PharmD, Ferreri CJ, Shune LO, DeJarnette S, Ouchveridze E, Susanibar-Adaniya S, Portuguese AJ, Forsberg PA, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Eberwein E, PharmD, Lin C, Blue B, Raza S, Lin Y, Joseph P, Atrash S, Sborov DW, Voorhees PM, Anwer F, Hansen DK, Patel KK, Sidana S, Cowan AJ, Anderson Jr LD, Richard S, Garfall AL, Lee HC, Khouri J. Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab. ASH 2024.
61. Lionel A, Seif S, Sun X, Feng L, Gensini L, Gabriel B, Lewis LS, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Ye J, Patel KP, Weber DM, Orlowski RZ, Thomas SK. Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma. ASH 2024.
62. Dang M, Lee HC, Bansal H, Acevedo-Calado MJ, Qin L, Tan W, Moreno Rueda LY, Berrios D, Pasvolsky O, Gaballa MR, Becnel MR, Ye J, Patel KK, Lin P, Thomas SK, Weber DM, Wang L, Orlowski RZ. Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma. ASH 2024.
63. Peres LC, Richards A, Sidana S, Oswald LB, Dima D, Afrough A, Shune LO, Midha S, Castaneda O, Ferreri C, Davis JA, PharmD, Pasvolsky O, Dillard CM, Herr MM, Kocoglu MH, Atrash S, Blue B, Ouchveridze E, McGuirk JP, Wagner CB, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, Avila GD, Purvey S, Hosoya H, Mikkilineni L, Kaur G, Gaballa MR, Forsberg PA, Freeman CL, Janakiram M, Htut M, Asoori S, Kalariya N, Atanackovic D, Dhakal B, Khouri J, Raza S, Reshef R, Alsina M, Locke FL, Nadeem O, Anwer F, Anderson Jr LD, Richard S, Lin Y, Martin T, Voorhees PM, Patel KK, Hansen DK, Sborov DW. Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel. ASH 2024.
64. Dhakal B, Slade M, Narra R, Mohamed ME, Akhtar OS, Bansal H, Acevedo-Calado MJ, Pasvolsky O, Gaballa MR, Becnel MR, Weber DM, Patel KK, Thomas SK, Ye J, Kuhr F, Dong B, Powell S, Bui T, Mohan M, Pasquini MC, D'Souza A, Knysh H, Orlowski RZ, Albitar M, Hans C. Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. ASH 2024.
65. Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, Pasvolsky O, Razzo B, Banerjee R, Khouri J, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, DeJarnette S, Portuguese AJ, Gaballa MR, Avila GD, Susanibar-Adaniya S, Raza S, Herr MM, Ouchveridze E, Richards T, Hosoya H, Mikkilineni L, Kaur G, Schrum D, Castaneda O, Rossi A, Lin C, Forsberg PA, Lin Y, Atrash S, Sborov DW, Shain KH, Voorhees PM, Richard S, Garfall AL, Hansen DK, Sidana S, Patel KK, Cowan AJ, Anderson Jr LD, Lee HC, Anwer F, Ferreri C, Shune LO. Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. ASH 2024.
66. Dhakal B, Akhtar OS, Cowan AJ, Richard S, Friend R, Rees MJ, Costello P, Martinez MV, Wagner CB, Jensen A, Davis JA, Reshef R, Dima D, Banerjee R, Bhutani M, Nadeem O, Parrondo RD, Mikkilineni L, Raza S, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Hansen DK, Costa LJ, Sidana S. Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM). ASH 2024.

Book Chapters

1. Gaballa M, Ramos, CA. Overview of Normal Hematopoiesis. In: Benign Hematology, 1-24, 2019.

Letters to the Editor

1. Afrough, A, Hashmi, H, Hansen, DK, Sidana, S, Ahn, C, Peres, LC, Dima, D, Freeman, C, Puglianini, OC, Kocoglu, MH, Atrash, S, Voorhees, PM, Shune, L, McGuirk, J, Simmons, GL, Sborov, D, Davis, JA, Kaur, G, Sannareddy, A, Ferreri, C, Gaballa, MM, Goldsmith, SR, Nadeem, O, Midha, S, Wagner, C, Locke, FL, Patel, K, Khouri, J, Anderson, L, Lin, Y. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood cancer journal 14, 2024.